Pulling RANK.

Denosumab, an inhibitor of RANKL that prevents osteoclast maturation, has been suggested to prevent bone mets in women with early-stage breast cancer. The large D-CARE trial has now put it back in its place, squarely outside the realm of oncologic therapeutics, as it conferred no significant improvement in bone mets-free survival. | Coleman, Lancet Oncol 2019